Edition:
United States

CytoDyn Inc (CYDY.PK)

CYDY.PK on OTC Markets Group

0.64USD
22 Sep 2017
Change (% chg)

-- (--)
Prev Close
$0.64
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
132,277
52-wk High
$0.84
52-wk Low
$0.46

Chart for

About

CytoDyn Inc. is a clinical-stage biotechnology company. The Company is focused on the clinical development and commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The Company's lead product candidate, PRO 140, belongs to a class of HIV therapies known as entry inhibitors... (more)

Overall

Beta: 0.46
Market Cap(Mil.): $99.90
Shares Outstanding(Mil.): 156.10
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 60.89 15.95
EPS (TTM): -- -- --
ROI: -- 0.19 15.19
ROE: -- 2.32 13.87

BRIEF-Cytodyn's Pro 140 for treating HIV deemed too broad for orphan drug designation by FDA

* Potential for Cytodyn's PRO 140 for treating HIV patients deemed too broad for orphan drug designation by the FDA

Apr 17 2017

Earnings vs. Estimates